GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PMV Pharmaceuticals Inc (NAS:PMVP) » Definitions » 9-Day RSI

PMV Pharmaceuticals (PMV Pharmaceuticals) 9-Day RSI : 58.80 (As of Apr. 30, 2024)


View and export this data going back to 2020. Start your Free Trial

What is PMV Pharmaceuticals 9-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2024-04-30), PMV Pharmaceuticals's 9-Day RSI is 58.80.

The industry rank for PMV Pharmaceuticals's 9-Day RSI or its related term are showing as below:

PMVP's 9-Day RSI is ranked worse than
79.72% of 1573 companies
in the Biotechnology industry
Industry Median: 47 vs PMVP: 58.80

Competitive Comparison of PMV Pharmaceuticals's 9-Day RSI

For the Biotechnology subindustry, PMV Pharmaceuticals's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PMV Pharmaceuticals's 9-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PMV Pharmaceuticals's 9-Day RSI distribution charts can be found below:

* The bar in red indicates where PMV Pharmaceuticals's 9-Day RSI falls into.



PMV Pharmaceuticals  (NAS:PMVP) 9-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PMV Pharmaceuticals  (NAS:PMVP) 9-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


PMV Pharmaceuticals 9-Day RSI Related Terms

Thank you for viewing the detailed overview of PMV Pharmaceuticals's 9-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


PMV Pharmaceuticals (PMV Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1 Research Way, Princeton, NJ, USA, 08536
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
Executives
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Leila Alland officer: Chief Medical Officer C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Deepika Jalota officer: SVP, Regulatory Affairs and QA C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Orbimed Capital Gp V Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Kirsten Flowers director C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Thilo Schroeder director, 10 percent owner C/O NEXTECH INVEST LTD., BAHNHOFSTRASSE 18, ZURICH V8 8001
Arnold J Levine director C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015
Winston Kung officer: COO, CFO C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
David Henry Mack director, officer: President and CEO ONE EMBARCADERO CENTER, SUITE 3700, SAN FRANCISCO CA 94111
Euclidean Capital Llc 10 percent owner 160 FIFTH AVE, 9TH FL, NEW YORK NY 10010
James H Simons 10 percent owner RENAISSANCE TECHNOLOGIES LLC, 800 THIRD AVE, NEW YORK NY 10022
Greenland A Llc 10 percent owner C/O EUCLIDEAN CAPITAL LLC, 160 FIFTH AVE, 9TH FL, NEW YORK NY 10010

PMV Pharmaceuticals (PMV Pharmaceuticals) Headlines

From GuruFocus